Matthew Rabinowitz Ph.D.
Net Worth
Last updated:
What is Matthew Rabinowitz Ph.D. net worth?
The estimated net worth of Dr. Matthew Rabinowitz Ph.D. is at least $502,965,035 as of 13 Dec 2024. He owns shares worth $382,412,151 as insider, has earned $115,410,284 from insider trading and has received compensation worth at least $5,142,600 in Natera, Inc..
What is the salary of Matthew Rabinowitz Ph.D.?
Dr. Matthew Rabinowitz Ph.D. salary is $514,260 per year as Co-Founder & Executive Chairman in Natera, Inc..
How old is Matthew Rabinowitz Ph.D.?
Dr. Matthew Rabinowitz Ph.D. is 52 years old, born in 1973.
What stocks does Matthew Rabinowitz Ph.D. currently own?
As insider, Dr. Matthew Rabinowitz Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Natera, Inc. (NTRA) | Co-Founder & Executive Chairman | 2,389,180 | $160.06 | $382,412,151 |
What does Natera, Inc. do?
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Matthew Rabinowitz Ph.D. insider trading
Natera, Inc.
Dr. Matthew Rabinowitz Ph.D. has made 79 insider trades between 2015-2024, according to the Form 4 filled with the SEC. Most recently he sold 5,300 units of NTRA stock worth $892,282 on 13 Dec 2024.
The largest trade he's ever made was exercising 732,831 units of NTRA stock on 19 Jun 2016. As of 13 Dec 2024 he still owns at least 2,389,180 units of NTRA stock.
Natera key executives
Natera, Inc. executives and other stock owners filed with the SEC:
- Dr. Matthew Rabinowitz Ph.D. (52) Co-Founder & Executive Chairman
- Mr. Jonathan Sheena (52) Co-Founder & Director
- Mr. Michael Brophy (45) Chief Financial Officer
- Mr. Robert A. Schueren (63) Chief Operating Officer
- Mr. Steve Leonard Chapman (46) Chief Executive Officer, Pres & Director